Combined IL-21 and IFNα treatment limits inflammation and delay viral rebound in ART-treated, SIV-infected macaques

Size: px
Start display at page:

Download "Combined IL-21 and IFNα treatment limits inflammation and delay viral rebound in ART-treated, SIV-infected macaques"

Transcription

1 Combined and IFNα treatment limits inflammation and delay viral rebound in ART-treated, SIV-infected macaques Mirko Paiardini Associate Professor, Emory University School of Medicine Yerkes National Primate Research Center IAS Cure & Cancer Forum Paris, France

2 Interleukin-21 treatment in SIV-infected RMs o Th17 cell maintenance is severely impaired in the absence of (Nurieva, Nature 27; Korn, Nature 27; Yang, Nature 28) o Paucity of -producing CD4+ T cells is associated with Th17 depletion in SIVinfected RMs (Micci, Blood 212); o Loss of function of intestinal IL-17 producing cells contributes to inflammation and viral persistence in SIV-infected RMs (Ryan, PLoS Pathogens 216) o treatment in acute SIV infection preserves Th17 cells and reduces microbial translocation (Micci, PLoS Pathogens 214) o treatment in ART-suppressed, SIV-infected RMs reduces residual inflammation and viral persistence (Micci, J Clin Invest 215)

3 limits intestinal T cell activation and proliferation Treated Treated %CD4 HLA-DR + CD38 + T cells RB P=.3 P=.11 P<.1 P<.1 P=.2 %CD8 HLA-DR + CD38 + T cells RB P=.21 P=.2477 P<.1 P<.1 P=.12 days on ART pre-art days on ART pre-art Average fold change vs day 58 (pre-art) %CD4 + Ki-67 + T cells RB o o 2 1 Average fold change vs day 58 (pre-art) P=.3 P=.17 day 58 day 84 day 256 Treated P<.1 But modestly reduces plasma P=.19 P=.21 P=.12 viremia upon ART-interruption No differences in timing of rebound No significant differences in viremia at any experimental points Micci L, J Clin Invest 215

4 Rationale and Study design Phase 1 Gr. 1: ART; #7 RMs Gr. 2: ART+IL21+IFN-α; #14 RMs d35 p.i. r r IFN-α SIVmac239 ART (TDF+FTC+DTG) Weeks Relative to infection LOD: 3 copies/ml A: ART Inflammation Antiviral functions B: ART + + IFNα Inflammation Antiviral functions Time Normalized Read Count 15 1 Time p<.1 + TX IFIT2 MX1 OAS2 MX2 SAMHD1 STAT1 IFIT3 IFI16 GBP1 IFI6 ISG2 ISG15 OAS3 OASL OAS1 IFI27 IRF7 CXCL1 TRIM5 IFIH1 CCL8 APOBEC3G STAT2 IFIT5 IFI44 RTP4 CHMP5 ISG expression by RNAseq in total PBMCs

5 +IFNα treated RMs maintain low levels of activation on ART CD4+ T cells CD8+ T cells PB %CD4 + Mem. HLA-DR + CD38 + T cells PB * + TX ** ** ** %CD8 + Mem. HLA-DR + CD38 + T cells PB * + Tx Days Post Infection Days Post Infection RB %CD4 + Mem. HLA-DR + CD38 + T cells RB Days Post Infection + TX %CD8 + Mem. HLA-DR + CD38 + T cells RB Days Post Infection Treated

6 Infectious units per million (IUPM) In fe c tio u s u n its p e r m ilio n (IU P M ) C D 4 T c e lls (L N ) +IFNα treated RMs show reduced viral on ART controls + IFNα + TX RPk11 & RNa12 (PTCs) excluded Rectal biopsies CD4+ T cells from LN c A R T P =. 9 SIVmac 239 DNA copies per 1 6 Tot. CD4 (RB) pre-art P=.1 P=.6 P=.1 on-art IF N + IFNα c o n o Longitudinal measurements including post but pre IFNα are pending Additional QVOA analyses in purified CD4+ T cells from LN are pending d35 IL21+ d35 CTRS d37 IL21+ d37 CTRS d a d 3 7 c trs

7 percent of viremic RMs 1 +IFNα treated RMs show delayed and RPk11 & RNa12 excluded (PTCs) reduced viral rebound after ATI plasma viral load betweem +peg-ifn a vs. Gr. 1: ART; #7 RMs Gr. 2: ART+IL21+IFN-α; #14 RMs Viral Rebound proportions post-art cessation 5/5 d35 p.i. r r Phase 1 SIVmac239 P=.2 ART (TDF+FTC+DTG) 2/8 + peg- TX IFN-α Phase 2 Viral rebound Phase 3 P=.5 Necropsy Weeks Relative to infection cut-off: 2 copies/ml 2 2 Control /8 IL21+peg-IFNα Days after ART interruption days post-art interruption 7/8 7/8 Plasma SIVmac 239 RNA copies/ml d6 peg+ Tx P=.4 for time window from day 6 to 44 ATI; 1.29 log 1 mean difference d6 controls d9 peg+ Tx P<.1 P<.1 peg- P<.1 d9 controls d13 peg+ Tx d13 controls d2 peg+ Tx d2 controls d3 peg- Tx d3 controls d44 peg-infa Tx. 44 d44 controls Kruskal-Wallis test: P=.9-3 groups separated Measures P=.2 - of Tx. vs. viral CTRS persistence post P=.25 - IgFc- Tx. vs. peg- Tx. ATI are pending What is happening after IFNα treatment has been discontinued? day 6 to 44: 1.29 log 1 mean difference

8 Preliminary conclusions + IFNα administration resulted in: Reduced mucosal and systemic immune activation Reduced cell-associated SIV-DNA in GI tract Delayed and reduced viral rebound post ATI (still during IFNα treatment) IFNα treatment was not associated with deleterious effects on T cell levels or immune activation, either on ART or after ATI Multiple immunologic and virologic parameters (including replication competent virus) are pending (longitudinal, blood and tissues) Impact on viral persistence after discontinuation of IFNα needs to be determined

9 Acknowledgments Paiardini Lab *Luca Micci Justin Harper *Sara Paganini Colin King Hong Wong Maria Pino Kristina Ortiz Emory Genomic Core Steven Bosinger Greg Tharp Nirav Patel NCI/Frederick Jeffrey Lifson Jacob Estes CASE Western Rafick Sekaly Susan Ribeiro Michael Lederman Gilead/ViiV Romas Geleziunas Jim Demarest Support NIH/NIAID amfar Emory CFAR Qura Therapeutics Emory - YNPRC Barbara Cervasi Guido Silvestri Paul Johnson Stephanie Ehnert Sherrie Jean Elizabeth Strobert U. Of Lafayette Francois Villinger *Former members Post doc positions available (mirko.paiardini@emory.edu)

Interleukin-21 combined with ART reduces inflammation and viral reservoir in SIV-infected macaques

Interleukin-21 combined with ART reduces inflammation and viral reservoir in SIV-infected macaques Interleukin-21 combined with ART reduces inflammation and viral reservoir in SIV-infected macaques Luca Micci, Emory University Emily S. Ryan, Emory University Rémi Fromentin, Université de Montréal Steven

More information

CTLA-4-expressing CD4 T cells are critical contributors to SIV viral persistence

CTLA-4-expressing CD4 T cells are critical contributors to SIV viral persistence IAS 2015 Towards an HIV Cure symposium Vancouver CTLA-4-expressing CD4 T cells are critical contributors to SIV viral persistence Colleen McGary Paiardini lab Emory University HIV reservoir prevents eradication

More information

JAK3 inhibitor administration in vivo in chronically SIV Infected Rhesus Macaques

JAK3 inhibitor administration in vivo in chronically SIV Infected Rhesus Macaques JAK3 inhibitor administration in vivo in chronically SIV Infected Rhesus Macaques preferentially depletes NK Cells Ladawan Kowawisatsut 1 Kovit Pattanapanyasat 1 Aftab A. Ansari 2 1 Department of Immunology

More information

Impact of Vorinostat Treatment of Non- Hodgkin s Lymphoma on HIV-1 Latent Reservoir

Impact of Vorinostat Treatment of Non- Hodgkin s Lymphoma on HIV-1 Latent Reservoir Impact of Vorinostat Treatment of Non- Hodgkin s Lymphoma on HIV-1 Latent Reservoir Adam Capoferri, Juan Carlos Ramos, Daniel Xu, Daniel I.S. Rosenbloom, Janet D. Siliciano, Robert F. Siliciano, Ariela

More information

Working Group#1: Trial Endpoints, Biomarkers & Definitions

Working Group#1: Trial Endpoints, Biomarkers & Definitions Working Group#1: Trial Endpoints, Biomarkers & Definitions Forum HIV Cure Project: Focus on The Regulatory Pathway June 17, 2014 www.hivforum.org Comments from co-chairs john mellors and mike miller www.hivforum.org

More information

Supplementary Materials for

Supplementary Materials for www.sciencetranslationalmedicine.org/cgi/content/full//49/eaao4/dc Supplementary Materials for TLR agonists induce transient viremia and reduce the viral reservoir in SIV-infected rhesus macaques on antiretroviral

More information

Eradication of HIV infection Not in my lifetime? or Just around the Corner? Michael M. Lederman, MD

Eradication of HIV infection Not in my lifetime? or Just around the Corner? Michael M. Lederman, MD Eradication of HIV infection Not in my lifetime? or Just around the Corner? Michael M. Lederman, MD Conflicts of Interest The pending clinical trials discussed here are funded by grant awards from Gilead

More information

With over 20 drugs and several viable regimens, the mo6vated pa6ent with life- long access to therapy can control HIV indefinitely, elimina6ng the

With over 20 drugs and several viable regimens, the mo6vated pa6ent with life- long access to therapy can control HIV indefinitely, elimina6ng the Towards an HIV Cure Steven G. Deeks, MD Professor of Medicine in Residence HIV/AIDS Division University of California, San Francisco (UCSF) WorldMedSchool; July 22, 2013 1 With over 20 drugs and several

More information

Establishment and Targeting of the Viral Reservoir in Rhesus Monkeys

Establishment and Targeting of the Viral Reservoir in Rhesus Monkeys Establishment and Targeting of the Viral Reservoir in Rhesus Monkeys Dan H. Barouch, M.D., Ph.D. Center for Virology and Vaccine Research Beth Israel Deaconess Medical Center Ragon Institute of MGH, MIT,

More information

Inves&gación básica y curación del VIH-1

Inves&gación básica y curación del VIH-1 Inves&gación básica y curación del VIH-1 Javier Mar&nez-Picado 24 th Conference on Retroviruses and Opportunis6c Infec6ons UNIVERSITAT DE VIC Empezamos bien cart: How Early is Early Enough? Sáez-Cirion

More information

Module R: Recording the HIV Reservoir

Module R: Recording the HIV Reservoir Module R: Recording the HIV Reservoir Satish K. Pillai, Ph.D. MODULE LEADER Satish Pillai amfar Institute for HIV Cure Research Module R Team Michael Busch Timothy Henrich Sheila Keating Sulggi Lee Henry

More information

Innovative diagnostics for HIV, HBV and HCV

Innovative diagnostics for HIV, HBV and HCV Innovative diagnostics for HIV, HBV and HCV Dan Otelea National Institute for Infectious Diseases Bucharest, Romania Disclaimer No conflicts of interest Innovative diagnostics for HIV, HBV and HCV - is

More information

Can HIV be cured? (how about long term Drug free remission?)

Can HIV be cured? (how about long term Drug free remission?) Can HIV be cured? (how about long term Drug free remission?) Shirin Heidari International AIDS Society EC Think Tank meeting 27-28 October 2010 Luxemburg HAART can control HIV, cannot eradicate it Life

More information

PD-1 blockade during chronic SIV infection reduces hyperimmune activation and microbial translocation in rhesus macaques

PD-1 blockade during chronic SIV infection reduces hyperimmune activation and microbial translocation in rhesus macaques Brief report Related Commentary, page 1611 PD-1 blockade during chronic SIV infection reduces hyperimmune activation and microbial translocation in rhesus macaques Ravi Dyavar Shetty, 1 Vijayakumar Velu,

More information

Clinical Development of ABX464, drug candidate for HIV Functional Cure. Chief Medical Officer ABIVAX

Clinical Development of ABX464, drug candidate for HIV Functional Cure. Chief Medical Officer ABIVAX Clinical Development of ABX464, drug candidate for HIV Functional Cure Jean-Marc Steens, MD Chief Medical Officer ABIVAX 1 DECLARATION OF CONFLICT OF INTEREST GSK ABIVAX 2 ABX464: Mechanism of Action ABX464

More information

Availability of activated CD4+ T cells dictates the level of viremia in naturally SIV-infected sooty mangabeys

Availability of activated CD4+ T cells dictates the level of viremia in naturally SIV-infected sooty mangabeys Availability of activated CD4+ T cells dictates the level of viremia in naturally SIV-infected sooty mangabeys Nichole R. Klatt, Emory University Francois Villinger, Emory University Pavel Bostik, Emory

More information

Novel Approaches for the Assessment of the In Vivo Residual Virus Pool and Viral Eradication Strategies in SIV-infected Rhesus Macaques

Novel Approaches for the Assessment of the In Vivo Residual Virus Pool and Viral Eradication Strategies in SIV-infected Rhesus Macaques Towards an HIV Cure Pre-Conference Symposium 20 & 21 July 2012 Novel Approaches for the Assessment of the In Vivo Residual Virus Pool and Viral Eradication Strategies in SIV-infected Rhesus Macaques Gregory

More information

Copyright information:

Copyright information: Reduced Simian Immunodeficiency Virus Replication in Macrophages of Sooty Mangabeys Is Associated with Increased Expression of Host Restriction Factors Kiran Mir-Hudgeons, Emory University Maud Mavigner,

More information

SUPPLEMENTARY INFORMATION. Divergent TLR7/9 signaling and type I interferon production distinguish

SUPPLEMENTARY INFORMATION. Divergent TLR7/9 signaling and type I interferon production distinguish SUPPLEMENTARY INFOATION Divergent TLR7/9 signaling and type I interferon production distinguish pathogenic and non-pathogenic AIDS-virus infections Judith N. Mandl, Ashley P. Barry, Thomas H. Vanderford,

More information

CD4 Depletion in SIV-Infected Macaques Results in Macrophage and Microglia Infection with Rapid Turnover of Infected Cells

CD4 Depletion in SIV-Infected Macaques Results in Macrophage and Microglia Infection with Rapid Turnover of Infected Cells CD4 Depletion in SIV-Infected Macaques Results in Macrophage and Microglia Infection with Rapid Turnover of Infected Cells Luca Micci, Emory University Xavier Alvarez, Tulane University Robin I. Iriele,

More information

The Role of B Cell Follicles in HIV Replication and Persistence

The Role of B Cell Follicles in HIV Replication and Persistence The Role of B Cell ollicles in HIV Replication and Persistence Elizabeth Connick, M.D. Professor of Medicine Chief, Division of Infectious Diseases University of Arizona July 17, 2016 IAS 2016 Towards

More information

Early treatment of SIV plus macaques with an alpha(4)beta(7) mab alters virus distribution and preserves CD4(+) T cells in later stages of infection

Early treatment of SIV plus macaques with an alpha(4)beta(7) mab alters virus distribution and preserves CD4(+) T cells in later stages of infection Early treatment of SIV plus macaques with an alpha(4)beta(7) mab alters virus distribution and preserves CD4(+) T cells in later stages of infection Philip J. Santangelo, Emory University Claudia Cicala,

More information

SUPPLEMENTAL INFORMATIONS

SUPPLEMENTAL INFORMATIONS 1 SUPPLEMENTAL INFORMATIONS Figure S1 Cumulative ZIKV production by testis explants over a 9 day-culture period. Viral titer values presented in Figure 1B (viral release over a 3 day-culture period measured

More information

Approaching a Cure Daniel R. Kuritzkes, MD

Approaching a Cure Daniel R. Kuritzkes, MD Approaching a Cure Daniel R. Kuritzkes, MD Division of Infectious Diseases Brigham and Women s Hospital Harvard Medical School Disclosures The speaker is a consultant and/or has received speaking honoraria

More information

HIV Reservoirs in Developing Countries: Implication for HIV CURE Strategies

HIV Reservoirs in Developing Countries: Implication for HIV CURE Strategies HIV Reservoirs in Developing Countries: Implication for HIV CURE Strategies 10 th INTEREST CONFERENCE 2016, 3-6 TH May 2016, Yaoundé, Cameroon Cissy Kityo 1 ; Thomas Schacker 2 ; Francis Ssali 1 ; Jeffrey

More information

Viral Reservoirs and anti-latency interventions in nonhuman primate models of SIV/SHIV infection

Viral Reservoirs and anti-latency interventions in nonhuman primate models of SIV/SHIV infection Viral Reservoirs and anti-latency interventions in nonhuman primate models of SIV/SHIV infection Koen Van Rompay California National Primate Research Center University of California Davis Outline Introduction

More information

CROI 2016 Review: Immunology and Vaccines

CROI 2016 Review: Immunology and Vaccines Frontier AIDS Education and Training Center CROI 2016 Review: Immunology and Vaccines Meena Ramchandani MD MPH Acting Instructor, University of Washington March 2016 This presentation is intended for educational

More information

Professor Jonathan Weber

Professor Jonathan Weber HIV/AIDS at 30: Back to the Future BHIVA / Wellcome Trust Multidisciplinary Event to mark World AIDS Day 2011 British HIV Association (BHIVA) 2011 HIV/AIDS at 30: Back to the Future BHIVA / Wellcome Trust

More information

Hepatitis B. HBV Cure: Insights for the Biotechnology and the Research Analyst Community November 11, Lalo Flores, PhD Global Head HBV R&D

Hepatitis B. HBV Cure: Insights for the Biotechnology and the Research Analyst Community November 11, Lalo Flores, PhD Global Head HBV R&D Hepatitis B HBV Cure: Insights for the Biotechnology and the Research Analyst Community November 11, 2016 Lalo Flores, PhD Global Head HBV R&D Infectious Diseases Diseases Infectious 11 Janssen s Vision

More information

Preclinical Animal Models for HIV Cure Research in Children: Scientific Knowledge Gaps

Preclinical Animal Models for HIV Cure Research in Children: Scientific Knowledge Gaps Preclinical Animal Models for HIV Cure Research in Children: Scientific Knowledge Gaps NIAID Workshop, May 22-23, 2018 Nancy L. Haigwood, Oregon Health & Science University Mississippi baby case brought

More information

An integrated transcriptomic and functional genomic approach identifies a. type I interferon signature as a host defense mechanism against Candida

An integrated transcriptomic and functional genomic approach identifies a. type I interferon signature as a host defense mechanism against Candida Supplementary information for: An integrated transcriptomic and functional genomic approach identifies a type I interferon signature as a host defense mechanism against Candida albicans in humans Sanne

More information

Supplementary Figures. Supplementary Figure 1. Treatment schematic of SIV infection and ARV and PP therapies.

Supplementary Figures. Supplementary Figure 1. Treatment schematic of SIV infection and ARV and PP therapies. Supplementary Figures Supplementary Figure 1. Treatment schematic of SIV infection and ARV and PP therapies. Supplementary Figure 2. SIV replication and CD4 + T cell count. (A) Log SIVmac239 copies/ml

More information

Inves)gación básica y curación del VIH- 1

Inves)gación básica y curación del VIH- 1 Inves)gación básica y curación del VIH- 1 Javier Mar)nez- Picado (jmpicado@irsicaixa.es) 23 rd Conference on Retroviruses and Opportunis5c Infec5ons February 22-25, 2016 Boston, Massachuse8s UNIVERSITAT

More information

IAS 2013 Towards an HIV Cure Symposium

IAS 2013 Towards an HIV Cure Symposium In chronically HIV-1-infected patients long-term antiretroviral therapy initiated above 500 CD4/mm 3 achieves better HIV-1 reservoirs' depletion and T-cell count restoration IAS 2013 Towards an HIV Cure

More information

Impact of ART in Primary HIV infection on T cell immune exhaustion in Gut- associated lymphoid tissue: Implications for HIV persistence

Impact of ART in Primary HIV infection on T cell immune exhaustion in Gut- associated lymphoid tissue: Implications for HIV persistence Impact of ART in Primary HIV infection on T cell immune exhaustion in Gut- associated lymphoid tissue: Implications for HIV persistence THORNHILL J, MARTIN GE, HERRERA C, HOPKINS E, FIDLER S, FRATER J

More information

The Chimpanzee Model Of HCV: Antiviral Therapy

The Chimpanzee Model Of HCV: Antiviral Therapy The Chimpanzee Model Of HCV: Antiviral Therapy Antiviral Therapies in Chimpanzees PEG IFN + Ribavirin STAT C with DAA Protease Inhibitors Nucleoside analogues Polymerase Inhibitors NS5A Inhibitors Immunomodulators

More information

Alexander O. Pasternak, Mirte Scherpenisse, Ben Berkhout

Alexander O. Pasternak, Mirte Scherpenisse, Ben Berkhout Cell-associated HIV-1 unspliced to multiply spliced RNA ratio at 12 weeks ART correlates with markers of immune activation and apoptosis and predicts the CD4 + T-cell count at 96 weeks ART Alexander O.

More information

Received 4 December 2001/Accepted 29 April 2002

Received 4 December 2001/Accepted 29 April 2002 JOURNAL OF VIROLOGY, Aug. 2002, p. 8433 8445 Vol. 76, No. 16 0022-538X/02/$04.00 0 DOI: 10.1128/JVI.76.16.8433 8445.2002 Copyright 2002, American Society for Microbiology. All Rights Reserved. The Relationship

More information

Supplementary Information

Supplementary Information Supplementary Information Early Treatment of SIV+ macaques with an α 4 β 7 mab alters virus distribution and preserves CD4 + T cells in later stages of infection Philip J. Santangelo Ph.D 1#*, Claudia

More information

Over thousands of years, species-specific

Over thousands of years, species-specific T1 Natural SIV Hosts: Showing AIDS the Door Ann Chahroudi, 1,2 Steven E. Bosinger, 2 Thomas H. Vanderford, 2 Mirko Paiardini, 2,3 * Guido Silvestri 2,3 * Many species of African nonhuman primates are naturally

More information

Supplementary Materials

Supplementary Materials 1 Supplementary Materials Rotger et al. Table S1A: Demographic characteristics of study participants. VNP RP EC CP (n=6) (n=66) (n=9) (n=5) Male gender, n(%) 5 (83) 54 (82) 5 (56) 3 (60) White ethnicity,

More information

Inconsistent HIV reservoir dynamics and immune responses following anti-pd-1 therapy

Inconsistent HIV reservoir dynamics and immune responses following anti-pd-1 therapy Letter to Editor (Annals of Oncology): Inconsistent HIV reservoir dynamics and immune responses following anti-pd-1 therapy in cancer patients with HIV infection E. P. Scully 1,2,3, R. L. Rutishauser 4,

More information

Severe Depletion of Mucosal CD4 + T Cells in AIDS-Free Simian Immunodeficiency Virus-Infected Sooty Mangabeys

Severe Depletion of Mucosal CD4 + T Cells in AIDS-Free Simian Immunodeficiency Virus-Infected Sooty Mangabeys This information is current as of September 1, 2018. References Subscription Permissions Email Alerts Severe Depletion of Mucosal CD4 + T Cells in AIDS-Free Simian Immunodeficiency Virus-Infected Sooty

More information

Recent Insights into HIV Pathogenesis and Treatment: Towards a Cure

Recent Insights into HIV Pathogenesis and Treatment: Towards a Cure Recent Insights into HIV Pathogenesis and Treatment: Towards a Cure Deborah Persaud, M.D. Associate Professor Department of Pediatrics Division of Infectious Diseases Johns Hopkins University School of

More information

Dr Jintanat Ananworanich

Dr Jintanat Ananworanich BHIVA AUTUMN CONFERENCE 2014 Including CHIVA Parallel Sessions Dr Jintanat Ananworanich US Military HIV Research Program in Bethesda Maryland, USA 9-10 October 2014, Queen Elizabeth II Conference Centre,

More information

Table S1. Viral load and CD4 count of HIV-infected patient population

Table S1. Viral load and CD4 count of HIV-infected patient population Table S1. Viral load and CD4 count of HIV-infected patient population Subject ID Viral load (No. of copies per ml of plasma) CD4 count (No. of cells/µl of blood) 28 7, 14 29 7, 23 21 361,99 94 217 7, 11

More information

System Biology analysis of innate and adaptive immune responses during HIV infection

System Biology analysis of innate and adaptive immune responses during HIV infection System Biology analysis of innate and adaptive immune responses during HIV infection Model of T cell memory persistence and exhaustion Naive Ag+APC Effector TEM (Pfp, Gr.B, FasL, TNF) Ag stim. IL-2, IL-7,

More information

Rapid perforin upregulation directly ex vivo by CD8 + T cells is a defining characteristic of HIV elite controllers

Rapid perforin upregulation directly ex vivo by CD8 + T cells is a defining characteristic of HIV elite controllers Rapid perforin upregulation directly ex vivo by CD8 + T cells is a defining characteristic of HIV elite controllers Adam R. Hersperger Department of Microbiology University of Pennsylvania Evidence for

More information

SUPPLEMENTARY INFORMATION

SUPPLEMENTARY INFORMATION ` SUPPLEMENTAL FIGURES doi:10.1038/nature10003 Supplemental Figure 1: RhCMV/SIV vectors establish and indefinitely maintain high frequency SIV-specific T cell responses in diverse tissues: The figure shows

More information

IMMUNE RECONSTITUTION AND SKEWED RESPONSES AFTER ART START IN HIV INFECTED UGANDANS

IMMUNE RECONSTITUTION AND SKEWED RESPONSES AFTER ART START IN HIV INFECTED UGANDANS Dale and Betty Bumpers Vaccine Research Center National Institute of Allergy and Infectious Diseases National Institutes of Health Abst#_PP_25 IMMUNE RECONSTITUTION AND SKEWED RESPONSES AFTER ART START

More information

Therapeutic Immunization with Autologous DC Pulsed with Autologous Inactivated HIV-1 Infected Apoptotic Cells

Therapeutic Immunization with Autologous DC Pulsed with Autologous Inactivated HIV-1 Infected Apoptotic Cells Therapeutic Immunization with Autologous DC Pulsed with Autologous Inactivated HIV-1 Infected Apoptotic Cells Sharon A. Riddler, MD, MPH University of Pittsburgh May 2008 Slide 1 HIV and DC Vaccines During

More information

Functional Cure of SIVagm Infection in Rhesus Macaques Results in Complete Recovery of CD4 + T Cells and Is Reverted by CD8 + Cell Depletion

Functional Cure of SIVagm Infection in Rhesus Macaques Results in Complete Recovery of CD4 + T Cells and Is Reverted by CD8 + Cell Depletion Functional Cure of SIVagm Infection in Rhesus Macaques Results in Complete Recovery of CD4 + T Cells and Is Reverted by CD8 + Cell Depletion Ivona Pandrea 1,2,3, Thaidra Gaufin 4, Rajeev Gautam 4, Jan

More information

Models of HIV during antiretroviral treatment

Models of HIV during antiretroviral treatment Models of HIV during antiretroviral treatment Christina M.R. Kitchen 1, Satish Pillai 2, Daniel Kuritzkes 3, Jin Ling 3, Rebecca Hoh 2, Marc Suchard 1, Steven Deeks 2 1 UCLA, 2 UCSF, 3 Brigham & Womes

More information

Addressing key gaps in cure research through identification and treatment of hyperacute HIV infection in a resource-limited setting

Addressing key gaps in cure research through identification and treatment of hyperacute HIV infection in a resource-limited setting Addressing key gaps in cure research through identification and treatment of hyperacute HIV infection in a resource-limited setting Thumbi Ndung u, BVM, PhD KwaZulu-Natal Research Institute for Tuberculosis

More information

The Impact of Immunoglobulin in Acute HIV Infection on the HIV Reservoir: A Pilot Randomized Controlled Trial

The Impact of Immunoglobulin in Acute HIV Infection on the HIV Reservoir: A Pilot Randomized Controlled Trial The Impact of Immunoglobulin in Acute HIV Infection on the HIV Reservoir: A Pilot Randomized Controlled Trial Olubanke Davies Guy s & St Thomas NHS Foundation Trust BACKGROUND Immediate ART during acute

More information

DNA and Protein Vaccination Confers Protection Upon Mucosal Challenge with Heterologous SIVsmE660 (OA 10.04)

DNA and Protein Vaccination Confers Protection Upon Mucosal Challenge with Heterologous SIVsmE660 (OA 10.04) DNA and Protein Vaccination Confers Protection Upon Mucosal Challenge with Heterologous SIVsmE660 (OA 10.04) Rashmi Jalah Human Retrovirus Pathogenesis Section, Vaccine Branch, CCR, National Cancer Institute

More information

HIV viral load testing in the era of ART. Christian Noah Labor Lademannbogen, Hamburg

HIV viral load testing in the era of ART. Christian Noah Labor Lademannbogen, Hamburg HIV viral load testing in the era of ART Christian Noah Labor Lademannbogen, Hamburg 1 Life expectancy of patients on ART Data from the UK Collaborative HIV Cohort (UK CHIC) Requirements: Early diagnosis

More information

Impact of antiretroviral therapy on gut immunology and the HIV reservoir in elite controllers

Impact of antiretroviral therapy on gut immunology and the HIV reservoir in elite controllers Impact of antiretroviral therapy on gut immunology and the HIV reservoir in elite controllers Connie J Kim (Abstract #185) Session: Building Better Therapeutics November 19, 2013 10:00am HIV Elite Controllers

More information

EXPLORING THE IMPACT OF SEX DISCREPANCIES IN HIV TREATMENT AND CURE

EXPLORING THE IMPACT OF SEX DISCREPANCIES IN HIV TREATMENT AND CURE EXPLORING THE IMPACT OF SEX DISCREPANCIES IN HIV TREATMENT AND CURE CECILE DELILLE LAHIRI, M.D, M.SC ASSISTANT PROFESSOR DIVISION OF INFECTIOUS DISEASES MAY 18, 2016 OUTLINE Describe discrepancy between

More information

Endogenous CCL2 neutralization restricts HIV-1 replication in primary human macrophages by inhibiting viral DNA accumulation

Endogenous CCL2 neutralization restricts HIV-1 replication in primary human macrophages by inhibiting viral DNA accumulation Sabbatucci et al. Retrovirology (2015) 12:4 DOI 10.1186/s12977-014-0132-6 RESEARCH Open Access Endogenous CCL2 neutralization restricts HIV-1 replication in primary human macrophages by inhibiting viral

More information

Mother-to-Infant Transmission of Simian Immunodeficiency Virus Is Rare in Sooty Mangabeys and Is Associated with Low Viremia

Mother-to-Infant Transmission of Simian Immunodeficiency Virus Is Rare in Sooty Mangabeys and Is Associated with Low Viremia JOURNAL OF VIROLOGY, June 2011, p. 5757 5763 Vol. 85, No. 12 0022-538X/11/$12.00 doi:10.1128/jvi.02690-10 Copyright 2011, American Society for Microbiology. All Rights Reserved. Mother-to-Infant Transmission

More information

Animal models in HIV cure research.

Animal models in HIV cure research. Animal models in HIV cure research. Luca Micci, Yerkes National Primate Research Center Mirko Paiardini, Emory University Colleen S. McGary, Yerkes National Primate Research Center Journal Title: Journal

More information

David Verhoeven, Sumathi Sankaran, Melanie Silvey, and Satya Dandekar*

David Verhoeven, Sumathi Sankaran, Melanie Silvey, and Satya Dandekar* JOURNAL OF VIROLOGY, Apr. 2008, p. 4016 4027 Vol. 82, No. 8 0022-538X/08/$08.00 0 doi:10.1128/jvi.02164-07 Copyright 2008, American Society for Microbiology. All Rights Reserved. Antiviral Therapy during

More information

Primate models of SIV infection: Differenct susceptibility of African green monkeys and macaques to develop AIDS

Primate models of SIV infection: Differenct susceptibility of African green monkeys and macaques to develop AIDS Les Pensières Animal Models, 2011 Primate models of SIV infection: Differenct susceptibility of African green monkeys and macaques to develop AIDS Michaela Müller-Trutwin Unité de Régulation des Infections

More information

The potential role of PD-1/PD-L1 blockade in HIV Remission and Cure Strategies

The potential role of PD-1/PD-L1 blockade in HIV Remission and Cure Strategies The potential role of PD-1/PD-L1 blockade in HIV Remission and Cure Strategies Stephen Mason Director, Discovery Virology Bristol-Myers Squibb Community Cure Workshop 2015 Sunday, Feb 22, 2015 Seattle,

More information

Can HPV, cervical neoplasia or. HIV transmission?

Can HPV, cervical neoplasia or. HIV transmission? Interactions between HPV and HIV: STIs and HIV shedding, regulation of HPV by HIV, and HPV VLP influence upon HIV Jennifer S. Smith Department of Epidemiology pd University of North Carolina Can HPV, cervical

More information

cure research HIV & AIDS

cure research HIV & AIDS Glossary of terms HIV & AIDS cure research Antiretroviral Therapy (ART) ART involves the use of several (usually a cocktail of three or more) antiretroviral drugs to halt HIV replication. ART drugs may

More information

Professor Anna Maria Geretti

Professor Anna Maria Geretti THIRD JOINT CONFERENCE OF BHIVA AND BASHH 2014 Professor Anna Maria Geretti Institute of Infection & Global Health, University of Liverpool 1-4 April 2014, Arena and Convention Centre Liverpool THIRD JOINT

More information

Therapeutic Efficacy of a TLR7 Agonist for HBV Chronic Infection in Chimpanzees

Therapeutic Efficacy of a TLR7 Agonist for HBV Chronic Infection in Chimpanzees Therapeutic Efficacy of a TLR7 Agonist for HBV Chronic Infection in Chimpanzees Robert Lanford 1, Bernadette Guerra 1, Deborah Chavez 1, Vida L. Hodara 1, Xubin Zheng 2, Grushenka Wolfgang 3, Daniel B.

More information

PROSPECTS FOR HIV CURE IN ADULTS. Nov 11 th 2013 John Frater

PROSPECTS FOR HIV CURE IN ADULTS. Nov 11 th 2013 John Frater PROSPECTS FOR HIV CURE IN ADULTS FIS 2013 Nov 11 th 2013 John Frater April 29 th 2013; Telegraph online THE COMPONENTS OF A CURE. What is cure? Issues to consider: Post treatment control the benefit of

More information

Therapeutic strategies for immune reconstitution in acquired immunodeficiency syndrome

Therapeutic strategies for immune reconstitution in acquired immunodeficiency syndrome 30 1, 1, 2, 3 1. ( ), 201508; 2., 200040; 3., 200032 : ( AIDS) ( HIV) 20 90,,,,,, AIDS, CD4 + T ( CTL), HIV, : ; ; Therapeutic strategies for immune reconstitution in acquired immunodeficiency syndrome

More information

No Conflict of Interest

No Conflict of Interest No Conflict of Interest Aging and HIV Co-Morbidities: A Challenge for Engagement in Care Maria L Alcaide M.D. Division of Infectious Diseases University of Miami Miller School of Medicine Objectives Understand

More information

Pathogenesis Update Robert F. Siliciano, MD, PhD

Pathogenesis Update Robert F. Siliciano, MD, PhD Pathogenesis Update Robert F. Siliciano, MD, PhD Professor of Medicine and Molecular Biology and Genetics Johns Hopkins University School of Medicine Investigator, Howard Hughes Medical Institute HIV-1

More information

Therapeutic DNA Vaccine Induces Broad T Cell Responses in the Gut and Sustained Protection from Viral Rebound and AIDS in SIV-Infected Rhesus Macaques

Therapeutic DNA Vaccine Induces Broad T Cell Responses in the Gut and Sustained Protection from Viral Rebound and AIDS in SIV-Infected Rhesus Macaques Therapeutic DNA Vaccine Induces Broad T Cell Responses in the Gut and Sustained Protection from Viral Rebound and AIDS in SIV-Infected Rhesus Macaques Deborah Heydenburg Fuller 1,2,3 * a, Premeela Rajakumar

More information

Supervised Treatment Interruption (STI) in an Urban HIV Clinical Practice: A Prospective Analysis.

Supervised Treatment Interruption (STI) in an Urban HIV Clinical Practice: A Prospective Analysis. Supervised Treatment Interruption (STI) in an Urban HIV Clinical Practice: A Prospective Analysis. J.L. YOZVIAK 1, P. KOUVATSOS 2, R.E. DOERFLER 3, W.C. WOODWARD 3 1 Philadelphia College of Osteopathic

More information

Antiretroviral Therapy in Simian Immunodeficiency Virus-Infected Sooty Mangabeys: Implications for AIDS Pathogenesis

Antiretroviral Therapy in Simian Immunodeficiency Virus-Infected Sooty Mangabeys: Implications for AIDS Pathogenesis Antiretroviral Therapy in Simian Immunodeficiency Virus-Infected Sooty Mangabeys: Implications for AIDS Pathogenesis Francesca Calascibetta, Emory University Luca Micci, Emory University Diane Carnathan,

More information

Damaged Intestinal Epithelial Integrity Linked to Microbial Translocation in Pathogenic Simian Immunodeficiency Virus Infections

Damaged Intestinal Epithelial Integrity Linked to Microbial Translocation in Pathogenic Simian Immunodeficiency Virus Infections Damaged Intestinal Epithelial Integrity Linked to Microbial Translocation in Pathogenic Simian Immunodeficiency Virus Infections Jacob D. Estes 1 *, Levelle D. Harris 2, Nichole R. Klatt 2, Brian Tabb

More information

Sustained HIV- 1 remission following homozygous CCR5 delta- 32 allogeneic haemopoetic stem cell transplantion

Sustained HIV- 1 remission following homozygous CCR5 delta- 32 allogeneic haemopoetic stem cell transplantion Sustained HIV- 1 remission following homozygous CCR5 delta- 32 allogeneic haemopoetic stem cell transplantion R Gupta 1, A Abdulijawad 2, L McCoy 2, D Peppa 3, M Salgado 4, J Martinez- Picado 4, A Wensing

More information

Virus-like particle vaccine activates and promotes B cell differentiation to IgG2a producing plasma cells Qizhi Cathy Yao, M.D., Ph.D.

Virus-like particle vaccine activates and promotes B cell differentiation to IgG2a producing plasma cells Qizhi Cathy Yao, M.D., Ph.D. Virus-like particle vaccine activates and promotes B cell differentiation to IgG2a producing plasma cells Qizhi Cathy Yao, M.D., Ph.D. Molecular Surgeon Research Center Michael E. DeBakey Department of

More information

Management of patients with antiretroviral treatment failure: guidelines comparison

Management of patients with antiretroviral treatment failure: guidelines comparison The editorial staff Management of patients with antiretroviral treatment failure: guidelines comparison A change of therapy should be considered for patients if they experience sustained rebound in viral

More information

DNA Genotyping in HIV Infection

DNA Genotyping in HIV Infection Frontier AIDS Education and Training Center DNA Genotyping in HIV Infection Steven C. Johnson M.D. Director, University of Colorado HIV/AIDS Clinical Program; Professor of Medicine, Division of Infectious

More information

Supplementary Figure 1. Gating strategy and quantification of integrated HIV DNA in sorted CD4 + T-cell subsets.

Supplementary Figure 1. Gating strategy and quantification of integrated HIV DNA in sorted CD4 + T-cell subsets. Supplementary information HIV reservoir size and persistence are driven by T-cell survival and homeostatic proliferation. Chomont, N., M. El Far, P. Ancuta, L. Trautmann, F. A. Procopio, B. Yassine-Diab,

More information

Journal of Infectious Diseases Advance Access published July 11, Effect of Antiretroviral Therapy on HIV Reservoirs in Elite Controllers

Journal of Infectious Diseases Advance Access published July 11, Effect of Antiretroviral Therapy on HIV Reservoirs in Elite Controllers Journal of Infectious Diseases Advance Access published July 11, 2013 1 Effect of Antiretroviral Therapy on HIV Reservoirs in Elite Controllers Tae-Wook Chun 1,6, J. Shawn Justement 1, Danielle Murray

More information

Low immune activation despite high levels of pathogenic HIV-1 results in long-term asymptomatic disease

Low immune activation despite high levels of pathogenic HIV-1 results in long-term asymptomatic disease Low immune activation despite high levels of pathogenic HIV-1 results in long-term asymptomatic disease Shailesh K. Choudhary 1 *, Nienke Vrisekoop 2 *, Christine A. Jansen 2, Sigrid A. Otto 2, Hanneke

More information

I declare that I have no financial conflicts of interest

I declare that I have no financial conflicts of interest I declare that I have no financial conflicts of interest Cytotoxic T-Lymphocytes Eliminate Defective HIV Proviruses Without Impacting Infectious Reservoirs R. Brad Jones Assistant Professor The George

More information

Destruction of the Residual Active HIV-1 Reservoir by Env-specific Immunotoxin

Destruction of the Residual Active HIV-1 Reservoir by Env-specific Immunotoxin Destruction of the Residual Active HIV-1 Reservoir by Env-specific Immunotoxin J. Victor Garcia-Martinez, Ph.D. University of North Carolina, at Chapel Hill IAS 2013 Towards an HIV Cure Symposium Delivering

More information

CD8+ Lymphocytes Control Viral Replication in SIVmac239-Infected Rhesus Macaques without Decreasing the Lifespan of Productively Infected Cells

CD8+ Lymphocytes Control Viral Replication in SIVmac239-Infected Rhesus Macaques without Decreasing the Lifespan of Productively Infected Cells CD8+ Lymphocytes Control Viral Replication in SIVmac239-Infected Rhesus Macaques without Decreasing the Lifespan of Productively Infected Cells The Harvard community has made this article openly available.

More information

Are Immune Modulators Really Needed to Cure HBV infection?

Are Immune Modulators Really Needed to Cure HBV infection? Are Immune Modulators Really Needed to Cure HBV infection? Harry L.A. Janssen Francis Family Chair of Hepatology Director Toronto Centre for Liver Disease University Health Network University of Toronto,

More information

Deconvolution of Heterogeneous Wound Tissue Samples into Relative Macrophage Phenotype Composition via Models based on Gene Expression

Deconvolution of Heterogeneous Wound Tissue Samples into Relative Macrophage Phenotype Composition via Models based on Gene Expression Electronic Supplementary Material (ESI) for Integrative Biology. This journal is The Royal Society of Chemistry 2017 Supplementary Information for: Deconvolution of Heterogeneous Wound Tissue Samples into

More information

PROPOSAL FOR THE DEVELOPMENT OF AN INTERNATIONAL REFERENCE PREPARATION FOR HEPATITIS D VIRUS RNA

PROPOSAL FOR THE DEVELOPMENT OF AN INTERNATIONAL REFERENCE PREPARATION FOR HEPATITIS D VIRUS RNA PROPOSAL FOR THE DEVELOPMENT OF AN INTERNATIONAL REFERENCE PREPARATION FOR HEPATITIS D VIRUS RNA SoGAT Clinical Diagnostics II 30 September / 1 October 2009, Istanbul Michael Chudy Julia Kreß C. Micha

More information

Additional Presentation Demonstrates Potential Mechanisms for Unprecedented HIV Reservoir Depletion by SB-728-T

Additional Presentation Demonstrates Potential Mechanisms for Unprecedented HIV Reservoir Depletion by SB-728-T September 8, 2014 Sangamo BioSciences Announces Presentation At ICAAC of New Clinical Data Demonstrating Sustained Functional Control of Viremia in Multiple HIV- Infected Subjects Treated with SB-728-T

More information

Nonpathogenic SIV infection of African green monkeys induces a strong but rapidly controlled type I IFN response

Nonpathogenic SIV infection of African green monkeys induces a strong but rapidly controlled type I IFN response Research article Related Commentary, page 3512 Nonpathogenic SIV infection of African green monkeys induces a strong but rapidly controlled type I IFN response Béatrice Jacquelin, 1 Véronique Mayau, 1

More information

Inclusion/Exclusion Criteria

Inclusion/Exclusion Criteria The Immunomodulatory Effects of Intensification among ART-suppressed Patients with Incomplete CD4 Recovery Peter W. Hunt, Nancy Shulman, Tim Hayes, Viktor Dahl, Ma Somsouk, Nick Funderburg, Alan L. Landay,

More information

10th International Rotavirus Symposium Bangkok, Thailand

10th International Rotavirus Symposium Bangkok, Thailand Rotavirus Host Range Restriction and Innate Immunity: Mechanisms of Vaccine Attenuation Harry Greenberg MD Stanford University 10th International Rotavirus Symposium Bangkok, Thailand 09/19/12 B dsrna

More information

Marmoset-based infectious disease research under biocontainment conditions

Marmoset-based infectious disease research under biocontainment conditions Marmoset-based infectious disease research under biocontainment conditions Jean Patterson, PhD Texas Biomedical Research Institute October 22 nd, 2018 West Nile virus Common marmoset found to be equivalently

More information

Target Cell Availability, Rather than Breast Milk Factors, Dictates Mother-to-Infant Transmission of SIV in Sooty Mangabeys and Rhesus Macaques

Target Cell Availability, Rather than Breast Milk Factors, Dictates Mother-to-Infant Transmission of SIV in Sooty Mangabeys and Rhesus Macaques Target Cell Availability, Rather than Breast Milk Factors, Dictates Mother-to-Infant Transmission of SIV in Sooty Mangabeys and Rhesus Macaques Ann Chahroudi, Emory University Emily Cartwright, Emory University

More information

BEAT-HIV Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy

BEAT-HIV Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy BEAT-HIV Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy We are pleased to announce that the National Institutes of Health (NIH) has awarded nearly $23 million to co-principal

More information

La risposta immune all infezione da virus ebola. Chiara Agrati, PhD

La risposta immune all infezione da virus ebola. Chiara Agrati, PhD La risposta immune all infezione da virus ebola Chiara Agrati, PhD Pathogenetic mechanisms This virus infection is able to: - disable the immune system, preventing an effective protective immune response

More information

IAS 2016 Towards an HIV Cure Symposium Durban, South Africa.

IAS 2016 Towards an HIV Cure Symposium Durban, South Africa. Effect of vorinostat, hydroxychloroquine and maraviroc combination therapy on viremia following treatment interruption in individuals treated during acute HIV infection Eugène Kroon, Jintanat Ananworanich,

More information

CTLA-4 + PD-1 Memory CD4 + T Cells Critically Contribute to Viral Persistence in Antiretroviral Therapy-Suppressed, SIV-Infected Rhesus Macaques

CTLA-4 + PD-1 Memory CD4 + T Cells Critically Contribute to Viral Persistence in Antiretroviral Therapy-Suppressed, SIV-Infected Rhesus Macaques Article CTLA-4 + PD-1 Memory CD4 + T Cells Critically Contribute to Viral Persistence in Antiretroviral Therapy-Suppressed, SIV-Infected Rhesus Macaques Graphical Abstract Authors Colleen S. McGary, Claire

More information